This document discusses respiratory complications of rheumatic diseases. It covers causes of diffuse parenchymal lung disease including infections, drugs, and connective tissue diseases. Clinical evaluation involves assessing symptoms, signs, imaging like HRCT, lung function tests, and biopsies. Specific lung manifestations are discussed for diseases like rheumatoid arthritis, SLE, and scleroderma. Drugs that can cause interstitial lung disease or other pulmonary complications are also outlined. Future areas of research are mentioned.
A detailed description of sarcoidosis, pulmonary in specific but also covering the other systems. a rare entity in india or a better way to say, often an overlooked disease.
Practical approach to interstitial lung diseases Hamdi Turkey
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
A detailed description of sarcoidosis, pulmonary in specific but also covering the other systems. a rare entity in india or a better way to say, often an overlooked disease.
Practical approach to interstitial lung diseases Hamdi Turkey
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
Some of the types of interstitial lung disease include:
Interstitial pneumonia: Bacteria, viruses, or fungi may infect the interstitium of the lung. A bacterium called Mycoplasma pneumonia is the most common cause.
Idiopathic pulmonary fibrosis : A chronic, progressive form of fibrosis (scarring) of the interstitium. Its cause is unknown.
Nonspecific interstitial pneumonitis: Interstitial lung disease that's often present with autoimmune conditions (such as rheumatoid arthritis or scleroderma).
Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
Some of the types of interstitial lung disease include:
Interstitial pneumonia: Bacteria, viruses, or fungi may infect the interstitium of the lung. A bacterium called Mycoplasma pneumonia is the most common cause.
Idiopathic pulmonary fibrosis : A chronic, progressive form of fibrosis (scarring) of the interstitium. Its cause is unknown.
Nonspecific interstitial pneumonitis: Interstitial lung disease that's often present with autoimmune conditions (such as rheumatoid arthritis or scleroderma).
Describes the basic radiology of diffuse interstitial disease ,with differential diagnosis of reticular interstitial pattern and how to approach HRCT findings .
Describes the basic radiology of diffuse interstitial disease ,with differential diagnosis of nodular interstitial pattern and how to approach HRCT findings .
Chest findings often are a challange in both diagnosis and treatment of collagen vascular disease. We present here an HRCT perspective of chest findings in arthritis, HRCT chest should be done in all cases of unexplained arthritis.
Pulmonary manifestations of systemic diseases (non CTD)Sesha Sai
Pulmonary manifestations of systemic diseases other than connective tissue disorders like stem cell, endocrine, abdominal, neuromuscular, hematological, chest wall abnormalities
This presentation is about pulmonary manifestations of systemic vasculitis,in it m discussing about WEGNER,S GRANULOMATOSIS, churg-strauss syndrome and MPA
5. Clinical Evaluation - I
Clinical Assessment
• Detailed timescale
• Get all old chest X-rays
• Environmental, occupation, pets, travel
• Smoking and drug history
• Cardiac disease
• HIV risk
• Family history
6. Clinical Evaluation - II
Respiratory symptoms and signs
• Dyspnoea
• Cough, especially in lymphangitis, sarcoid,
CFA and COP
• Pleurisy (50% in SLE, 25% in RA)
• Chest pain - pneumothorax
• Haemoptysis
7. Clinical Evaluation - III
Clinical Findings
• Fine end respiratory crackles (up to 90%)
• Clubbing
(50% in CFA, 75% in RA-associated lung
disease)
• Pulmonary hypertension
• Cor pulmonale
8. Laboratory Investigations
• full blood count and eosinophils
• urea and electrolytes
• liver function tests
• rheumatoid factor
• anti-nuclear antibodies
• (ANCA, ABMA, ACE)
9. Imaging I
Diagnosis
• Chest X-ray
– may be normal at presentation
– very non-specific
• HRCT
– 94% sensitive, 85% sensitive
– radiation dose 7 times chest X-ray dose
10. Imaging II
Disease Activity and Diagnosis
• HRCT very specific for CFA and FA in relation
to pre-existing rheumatic disease
• Can delineate fibrosis
• Traction bronchiectasis
• Ground glass appearance of alveolitis
• Peripheral fibrosis is better survival predictor
than central fibrosis
11. Imaging III
Benefits of HRCT
• Increased likelihood of diagnosis from an
extensive disease and potential biopsy site
• Clinical and HRCT should give 80% of correct
diagnoses in DPLD
• Biopsy may not be needed
• Valuable in determining activity and prognosis
13. Lung function testing
Diagnosis
• Restrictive pattern commonest - often
combined with airflow obstruction
• Spirometry and gas transfer best measure
• Exercise testing not helpful
• Cannot distinguish inflammation and fibrosis
Monitoring
• Vital capacity and TLCO most appropriate
measures
• Inadequate data as serial predictors
14. Bronchoalveolar lavage
• Increased granulocytes in fibrosing
alveolitis with/without rheumatic disease
• Increased lymphocytes in granulomatous
or drug-induced toxicity
• Helpful in diagnosis of infection or
malignancy
• Role in monitoring unclear
15. Lung biopsy
• Needle biopsy useful for focal lesions
only
• Transbronchial biopsy good for sarcoid,
malignancy or COP
• Not useful for staging fibrosing alveolitis
• Open lung biopsy or VATS
16. Rheumatoid Arthritis -
Diffuse parenchymal lung disease
• Risk high in men, smokers, nodular RA, family
history, high RF or ANA
• Severity of joint disease not predictor of DPLD
• Differential diagnosis - infections, gold, MTX
Treatment
• Steroids alone (1 study) improved exercise
tolerance; COP markedly improved
• Immunosuppressants, especially azathioprine,
improved exercise tolerance
• Treat as CFA
17. Rheumatoid Arthritis -
Other pulmonary manifestations
Pleural disease
• pleural effusion 5%, pleuritic pain 20%
• commoner in males
• exudate with low glucose
• rheumatoid factor usually in high titres
(careful with empyema)
18. Rheumatoid Arthritis -
Other pulmonary manifestations
Pulmonary nodules
• 1-2cms; may cavitate, cause haemoptysis,
cause pneumothorax or become colonised
with aspergillus
Obliterative bronchiolitis
• Progressive airflow obstruction
• Primary or secondary to gold, sulphasalazine,
penicillamine or NSAID
19. Rheumatoid Arthritis -
Other pulmonary manifestations
• Cricoarytenoid arthritis
Especially females in association with
temporomandibular disease
• Vocal cord nodules
• Pulmonary and pleural infections
Worse with steroids
• Pulmonary arteritis
• Lung cancer
• Bullae and Pneumothorax
20. SLE - I
Pleural disease
• Pleuritis in up to 50%, may be recurrent
• Pleural effusion in 20%, usually exudate
• Also associated with pericarditis
• NSAIDs, rarely steroids and immunosuppressives
DPLD
• Infection most common cause
• Acute lupus pneumonitis 0.9% + alveolar
haemorrhage (17%) worse post partum
• Chronic pneumonitis 13%
• Treat as for CFS, results unclear
21. SLE - II
Other respiratory complications
• Pulmonary hypertension
• Pulmonary thromboembolism
• Respiratory muscle involvement and
shrinking lung syndrome
22. Scleroderma -
Interstitial fibrosis
• Interstitial fibrosis in 80%
• CXR abnormal in 13-78% but 44% with normal
CXR at presentation have abnormal HRCT
• DLCO sensitive, associated with anti Scl-70;
anti-centromere Ab often with normal DLCO
• DLCO<40% normal ⇒ 9% 5 year survival
DLCO>40% normal ⇒75% 5 year survival
• Treatment - some evidence for steroids and
cyclophosphamide
23. Scleroderma -
Pulmonary Hypertension
• Pulmonary hypertension in 50%
• Pulmonary artery pressure > 20mmHg at rest
• Primary pulmonary hypertension or secondary to
cardiac or interstitial lung disease
• 9% limited scleroderma have clinical pulmonary
hypertension
• 65% limited scleroderma have pulmonary
hypertension on biopsy or PM
• Isolated pulmonary hypertension, 40% 2yr survival
28. The Future
• Increased understanding of relationship
between
– intracellular matrix
– signalling proteins
– fibroblast proliferation
• Possible roles for interferons and
perfenidone